Tempest Therapeutics Q1 net loss widens on asset acquisition costs

Tempest Therapeutics

14/05/2026 21:31

Overview

US CAR-T therapy developer's Q1 net loss widened due to asset acquisition costs

Research and development expenses fell sharply as focus shifted to strategic alternatives

Company reported positive interim data from ongoing TPST-2003 clinical trials

Outlook

Tempest plans to initiate a U.S. registrational study of TPST-2003 in rrMM later in 2026

Company expects partner-funded BLA filing for TPST-2003 in China in 2027

Tempest says it will need to raise additional funds to expand its cash runway

Result Drivers

ASSET ACQUISITION COSTS - Co said net loss increased mainly due to one-time costs from acquiring new CAR-T assets

R&D EXPENSE SHIFT - Research and development expenses fell as co re-prioritized efforts toward strategic alternatives and asset acquisition

INCREASED ADMINISTRATIVE COSTS - General and administrative expenses rose due to one-time costs from the asset acquisition

Company press release: ID:nGNX2pKcvh

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$2.53
Q1 Net Income
-$27.70 mln
Q1 Operating Income
-$27.72 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Tempest Therapeutics Inc is $11.00, about 497.8% above its May 13 closing price of $1.84

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)